Delivery of cancer therapeutics using nanotechnology

Eun Kyung Lim, Eunji Jang, Kwangyeol Lee, Seungjoo Haam, Yong Min Huh

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems.

Original languageEnglish
Pages (from-to)294-317
Number of pages24
JournalPharmaceutics
Volume5
Issue number2
DOIs
Publication statusPublished - 2013 May 23

Fingerprint

Nanotechnology
Nanoparticles
Drug Carriers
Drug Delivery Systems
Neoplasms
Cataloging
Nanostructures
Drug Monitoring
Therapeutics
Group Psychotherapy
Early Diagnosis
Theranostic Nanomedicine

Keywords

  • Cancer
  • Drug delivery
  • Nanoparticles
  • Nanotechnology
  • Theranostic nanoparticles

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Delivery of cancer therapeutics using nanotechnology. / Lim, Eun Kyung; Jang, Eunji; Lee, Kwangyeol; Haam, Seungjoo; Huh, Yong Min.

In: Pharmaceutics, Vol. 5, No. 2, 23.05.2013, p. 294-317.

Research output: Contribution to journalArticle

Lim, Eun Kyung ; Jang, Eunji ; Lee, Kwangyeol ; Haam, Seungjoo ; Huh, Yong Min. / Delivery of cancer therapeutics using nanotechnology. In: Pharmaceutics. 2013 ; Vol. 5, No. 2. pp. 294-317.
@article{d937312703144786a721fc4ef8909ad9,
title = "Delivery of cancer therapeutics using nanotechnology",
abstract = "Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems.",
keywords = "Cancer, Drug delivery, Nanoparticles, Nanotechnology, Theranostic nanoparticles",
author = "Lim, {Eun Kyung} and Eunji Jang and Kwangyeol Lee and Seungjoo Haam and Huh, {Yong Min}",
year = "2013",
month = "5",
day = "23",
doi = "10.3390/pharmaceutics5020294",
language = "English",
volume = "5",
pages = "294--317",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Delivery of cancer therapeutics using nanotechnology

AU - Lim, Eun Kyung

AU - Jang, Eunji

AU - Lee, Kwangyeol

AU - Haam, Seungjoo

AU - Huh, Yong Min

PY - 2013/5/23

Y1 - 2013/5/23

N2 - Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems.

AB - Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems.

KW - Cancer

KW - Drug delivery

KW - Nanoparticles

KW - Nanotechnology

KW - Theranostic nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84877899798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877899798&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics5020294

DO - 10.3390/pharmaceutics5020294

M3 - Article

AN - SCOPUS:84877899798

VL - 5

SP - 294

EP - 317

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 2

ER -